High Throughput Screen for *Escherichia coli* Twin Arginine Translocation (Tat) Inhibitors

Umesh K. Bageshwar, Lynn VerPlank, Dwight Baker, Wen Dong, Shruthi Hamsanathan, Neal Whitaker, James C. Sacchettini, Siegfried M. Musser

1 Department of Molecular and Cellular Medicine, College of Medicine, Texas A&M Health Science Center, College Station, TX, United States of America, 2 Broad Institute, Cambridge, MA, United States of America, 3 Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX, United States of America

*smusser@tamhsc.edu*

Abstract

The twin arginine translocation (Tat) pathway transports fully-folded and assembled proteins in bacteria, archaea and plant thylakoids. The Tat pathway contributes to the virulence of numerous bacterial pathogens that cause disease in humans, cattle and poultry. Thus, the Tat pathway has the potential to be a novel therapeutic target. Deciphering the Tat protein transport mechanism has been challenging since the active translocon only assembles transiently in the presence of substrate and a proton motive force. To identify inhibitors of Tat transport that could be used as biochemical tools and possibly as drug development leads, we developed a high throughput screen (HTS) to assay the effects of compounds in chemical libraries against protein export by the *Escherichia coli* Tat pathway. The primary screen is a live cell assay based on a fluorescent Tat substrate that becomes degraded in the cytoplasm when Tat transport is inhibited. Consequently, low fluorescence in the presence of a putative Tat inhibitor was scored as a hit. Two diverse chemical libraries were screened, yielding average Z'-factors of 0.74 and 0.44, and hit rates of ~0.5% and 0.04%, respectively. Hits were evaluated by a series of secondary screens. Electric field gradient (Δψ) measurements were particularly important since the bacterial Tat transport requires a Δψ. Seven low IC$_{50}$ hits were eliminated by Δψ assays, suggesting ionophore activity. As Δψ collapse is generally toxic to animal cells and efficient membrane permeability is generally favored during the selection of library compounds, these results suggest that secondary screening of hits against electrochemical effects should be done early during hit validation. Though none of the short-listed compounds inhibited Tat transport directly, the screening and follow-up assays developed provide a roadmap to pursue Tat transport inhibitors.

Introduction

The targeting and transport of proteins across lipid membrane barriers is a fundamental process in all cells that is essential for growth, development and homeostasis. In general, ~30–50% of an organism’s proteome is transported across or inserted into membranes by a variety of...
protein translocation machineries [1,2]. In bacteria, most extra- 
cytoplasmic proteins are transported across or into the cytoplasmic membrane by one of two 
major pathways, the general secretory (Sec) pathway [3] or the twin arginine translocation (Tat) pathway [4].

The Tat pathway is unique because it transports fully-folded and assembled proteins (i.e.,
large, irregular-shaped macromolecules) without compromising the membrane’s role as a bar-
rier to ions and metabolites [4]. In addition, it requires the presence of a proton motive force
(PMF) to function, but not nucleoside triphosphates (NTPs) [5,6]. In bacteria, only the elec-
trical field gradient ($\Delta \psi$) component of the PMF is required for Tat transport [7]. The N-terminal
signal peptides (or ‘presequences’) of Tat precursor proteins contain a twin arginine consensus
motif (RR-motif)—hence the name Tat, for twin-arginine translocation [8]. In the bacterial
consensus motif, (S/T)RRxFLK, the arginine residues are almost invariant, whereas the other
amino acid residues occur with a frequency of > 50%. About 8% of E. coli cell-envelope pro-
teins (~30) are transported by the Tat machinery, and ~2/3 of these proteins contain prosthetic
groups, which are inserted into the proteins in the cytoplasm [9,10].

The E. coli Tat protein transport system contains four identified protein components, TatA,
TatB, TatC and TatE. Three of these proteins—TatA, TatB and TatE—are structurally similar,
and likely have a common origin [11]. They each have a single N-terminal transmembrane
domain and a C-terminal cytoplasmic domain [4,12]. TatC has six transmembrane domains
with both N- and C-termini facing the cytoplasm [13–15]. TatBC oligomers form the receptor
complex for Tat substrates [16,17]. The TatC X-ray structure reveals a glove-shaped pocket,
which can potentially accommodate a signal peptide hairpin that partially spans the bilayer
[15,18]. TatA and TatE form homo-oligomeric rings [19], suggesting that these proteins
can form translocation channels. The dominant model hypothesizes that TatA (or TatE) is
recruited to the TatBC-substrate complex in the presence of a PMF and forms the conduit nec-
essary for cargo transport [19,20]. Small molecules that perturb, inhibit or stabilize intermedi-
ates in this process are expected to be quite useful for deciphering the transport mechanism
and/or as in vitro or in vivo tools.

The Tat pathway is important for the pathogenicity of many bacteria [21]. In the case of M.
tuberculosis, which is responsible for ~2 million global deaths annually due to tuberculosis, the
Tat pathway appears essential for bacterial survival [22,23]. Though the Tat machinery is not
essential for the growth of most bacteria, Tat deletion strains usually exhibit significant growth
defects such as enhanced susceptibility to external agents (antibiotics and detergents), and/or
reduced virulence [24–27]. The widespread increase in drug-resistant pathogens, especially
many multidrug-resistant strains, and the shortage of new antimicrobials emphasizes the
importance of discovering and characterizing new antibiotics and antibiotic targets [28]. In
animals, the Tat system has only been found in aspiculate homoscleromorph sponges [29].
Since the Tat machinery is absent from higher animals including humans, a drug that inhibits
protein export through the Tat machinery with high specificity is expected to be effective in
neutralizing or attenuating the pathogenicity of numerous bacteria, possibly without, or with
few, side effects.

We describe herein a high throughput screening approach to identify small molecule inhibi-
tors of Tat transport that can be used to assist with the characterization and elucidation of the
Tat transport mechanism and as lead compounds for the development of antibiotics to benefit
human health. This screen is based on a fluorescent Tat substrate that becomes degraded when
Tat transport is inhibited. We screened 51,600 compounds from a local library and 337,881
compounds from the NIH’s Molecular Libraries Small Molecule Repository (MLSMR) at the
Broad Institute Probe Development Center (BIPDeC) (Cambridge, MA), a member of the
Molecular Libraries Probe Production Centers Network (MLPCN). The majority of lead com-
pounds obtained from the primary assay did not survive confirmation and dose response, and
the remaining compounds did not survive follow-up biochemical assays. Compared with a previous approach [30], the strengths of our screening protocol are in vitro biochemical assays that can verify whether the Tat machinery is a direct target of a putative inhibitor.

Results
Design of the HTS Assay
We developed a live cell-based high throughput screen (HTS) in which a C-terminal SsrA tag promotes the cytoplasmic degradation of a pre-protein when Tat-dependent protein export is inhibited or blocked. It was previously demonstrated that when Tat-dependent export of spTorA-GFP-SsrA (which consists of the signal peptide of TorA fused to GFP with a C-terminal SsrA tag) is impaired, the protein remaining in the cytoplasm is degraded by the ClpXP/ClpAP protease system [31]. Since the fluorescence emission of GFP overlaps significantly with the intrinsic fluorescence of Luria-Bertani (LB) media, we replaced the GFP domain with mCherry, designating the new fluorescent Tat substrate as spTorA-mCherry-SsrA (Fig 1A and 1B, S1 Fig). The fluorescence emission from mCherry does not overlap with the intrinsic fluorescence of LB media (Fig 1C).

The N-terminal signal peptide of TorA (spTorA) targets spTorA-mCherry-SsrA to the Tat system for export to the periplasm. At the same time, the C-terminal SsrA tag promotes ClpXP/ClpAP-dependent degradation of spTorA-mCherry-SsrA protein molecules in the cytoplasm. Thus, there is competition between the export and degradation pathways. The total cellular fluorescence arises from cytoplasmically-localized (and not degraded) mCherry protein (predominantly the full-length precursor spTorA-mCherry-SsrA) and periplasmically-localized mature protein (mCherry-SsrA). Due to the degradation of cytoplasmically-localized spTorA-mCherry-SsrA, the total mCherry fluorescence observed for wild type cell cultures should arise primarily from periplasmically-localized mCherry-SsrA. In contrast, when the Tat machinery is absent or blocked (e.g., by an inhibitor), a significant decrease in fluorescence is expected (Fig 1D).

Optimization of the Total mCherry Fluorescence Signal and Validation of Substrate Design Properties
For maximum sensitivity in a HTS, a strong signal is needed. We examined the strength of the mCherry fluorescence signal when the spTorA-mCherry-SsrA induction level was varied (0–100 mM arabinose) in wild type (Tat⁺) and TatABC overproduced (Tat+++) backgrounds. The total cellular fluorescence plateaued at 50–100 mM arabinose, and TatABC overproduction yielded an ~50% greater signal (Fig 2A). Cell fractionation and fluorescence microscopy analysis confirmed that the major fluorescent species in the Tat++ (spTorA-mCherry-SsrA) strain was periplasmically-localized mature protein (Fig 2B and 2C). Replacing the SsrA tag with a 6xHis-tag (yielding spTorA-mCherry-H6) resulted in an increase in cytoplasmic mCherry, confirming that the SsrA tag promotes cytoplasmic degradation of the spTorA-mCherry-SsrA protein. No periplasmic mCherry was observed in a Tat-deficient strain (ΔTat), confirming that the spTorA-mCherry-SsrA protein was indeed targeted to and transported by the Tat system (Fig 2B and 2C). No difference in total cellular fluorescence was observed if TatABC overproduction was induced at the same time as or 3 h before spTorA-mCherry-SsrA induction (Fig 2D). The total cellular fluorescence plateaued ~12 h after spTorA-mCherry-SsrA production was induced (Fig 2E). In summary, these data validate the spTorA-mCherry-SsrA protein as a suitable fluorescence substrate for use in a HTS.
Stability of the mCherry Fluorescence Signal

Since large HTSs require lengthy read times, we examined the stability of the mCherry fluorescence signal under Tat+ and Tat++ conditions. After 8 h of induction, spTorA-mCherry-SsrA production was repressed by incubating cultures at 4°C (Fig 3A), which blocks cell growth, or by the addition of 0.5% glucose (Fig 3B), which represses the arabinose promoter [32]. Both lower temperature and glucose addition stabilized the total cellular fluorescence signal for at least ~12 h, although there were lags of ~2 and ~4 h before the fluorescence signal stabilized under low temperatures.

Fig 1. Design of the HTS. (A) The fluorescent Tat precursor protein spTorA-mCherry-SsrA. The N-terminal TorA signal peptide (spTorA) targets the fluorescent protein mCherry (PDB: 2H5W) to the Tat machinery for transport to the periplasm, and the C-terminal SsrA-tag promotes cytoplasmic degradation of the protein. (B) Fluorescence spectra of LB media alone (black) and with cells producing spTorA-GFP-SsrA in the Tat++ background (green) (EX = 485 nm). Tat++ denotes strain MC4100(DE3) in which TatABC is overproduced from the pTatABC-Duet1 plasmid (see Methods). (C) Fluorescence spectra of LB media alone (black) and with cells producing spTorA-mCherry-SsrA (red) under the indicated conditions (EX = 587 nm). NaSCN collapses the Δψ across the inner membrane. For (B) and (C), cells with (Tat++) or without (∆Tat) TatABC were induced with the indicated proteins and then incubated for 12 h at 4°C (∆Tat denotes strain MC4100ΔTatABCDE; see Methods for more details). (D) Design of the HTS assay. The SsrA tag on spTorA-mCherry-SsrA promotes degradation of cytoplasmically-localized spTorA-mCherry-SsrA, and thus, periplasmically-localized mature Tat cargo (mCherry-SsrA) is the dominant contributor to the total mCherry cellular fluorescence. In the ∆Tat background, or in the presence of 30 mM NaSCN (positive control; simulated hit), the total cellular fluorescence is lower, as shown in (C). Due to the competition between transport of mCherry to the periplasm by the Tat machinery and degradation by the ClpXP/ClpAP protease system, low fluorescence in the presence of a putative Tat inhibitor was considered a hit. spTorA-mCherry-H6 (replacing the SsrA tag with a 6xHis-tag) is a control protein that is not degraded in the cytoplasm. OM = outer membrane; IM = inner membrane.

doi:10.1371/journal.pone.0149659.g001

Stability of the mCherry Fluorescence Signal

Since large HTSs require lengthy read times, we examined the stability of the mCherry fluorescence signal under Tat+ and Tat++ conditions. After 8 h of induction, spTorA-mCherry-SsrA production was repressed by incubating cultures at 4°C (Fig 3A), which blocks cell growth, or by the addition of 0.5% glucose (Fig 3B), which represses the arabinose promoter [32]. Both lower temperature and glucose addition stabilized the total cellular fluorescence signal for at least ~12 h, although there were lags of ~2 and ~4 h before the fluorescence signal stabilized under low temperatures.
temperature and glucose repression conditions, respectively. These experiments identified a timeframe in which we could read plates with minimal intra-plate and plate-to-plate variation.

**Effect of Oxidative Phosphorylation Inhibitors on In Vivo Tat Transport**

When screening for inhibitors via HTS, it is useful to include a known inhibitor as a positive control. Since the Δψ is required for bacterial Tat transport [7], we tested whether various
respiration inhibitors could be used to collapse the Δψ in vivo. In vitro, Tat transport is completely inhibited by the addition of both nigericin and valinomycin, which collapse the transmembrane pH gradient (ΔpH) and the Δψ, respectively [7]. High concentrations of nigericin and/or valinomycin (50 μM each) did not affect cell growth or mCherry fluorescence in culture (Fig 4A). This was unexpected since 2.5 μM of each these two ionophores are sufficient to completely block Tat transport in vitro [7]. NaSCN alone completely inhibits in vitro Tat transport, and, like valinomycin, NaSCN collapses the Δψ [7]. NaSCN (50 mM) reduced mCherry fluorescence by ~40% without affecting growth of E. coli cultures (Fig 4A). Dose response data showed that 30 mM NaSCN is sufficient to maximally reduce the mCherry fluorescence signal without affecting cell growth (Fig 4B). Thus, NaSCN appears more effective than valinomycin at inhibiting the Δψ in vivo, resulting in reduced Tat-dependent protein transport. Consequently, NaSCN was used throughout our screens as a positive control (simulated hit). Sodium azide is an inhibitor of cytochrome bo3, the terminal oxidase in the aerobic respiratory chain of E. coli [33–35]. As expected, azide inhibited cell growth and decreased the mCherry fluorescence signal by similar amounts (Fig 4A).

Sensitivity of Fluorescence Detection on Plates

We next tested whether cellular mCherry fluorescence could be detected at reasonable cell densities after growth in 384-well plates. Tat++ cells producing spTorA-mCherry-SsrA were serially diluted into 384-well plates and incubated at 25°C for 8 h. Dose-dependent absorbance (due to light scatter) and fluorescence signals were obtained. Under uninduced conditions, the fluorescence signals were negligible, but cell densities were unaffected, as expected. Purified spTorA-mCherry yielded a dose-dependent fluorescence signal and negligible A500, also as expected (Fig 4C). These results demonstrated a detectable range of cellular mCherry fluorescence signals on plates.

Outline of the HTS Assay

Having obtained the calibration and validation data described in the previous sections, we next established the protocol for the HTS. Details are provided in the Materials and Methods.
section. Here, we briefly summarize the assay. A single colony of *E. coli* strain MC4100(DE3) containing plasmids encoding TatABC and spTorA-mCherry-SsrA was inoculated into LB and grown overnight. The next morning, cells were transferred to fresh media, the production of TatABC and spTorA-mCherry-SsrA was induced, and cultures were aliquoted onto plates with
test compounds. NaSCN was included in control wells to simulate a hit. Cells were grown for 8 h, followed by incubation at 4°C overnight, and then read the next day. Setting the total cellular fluorescence obtained with spTorA-mCherry-H6 under Tat++ conditions to 100%, spTorA-mCherry-SsrA yielded a total cellular fluorescence signal of 63±14%, consistent with SsrA-induced degradation of the mCherry protein. The total cellular fluorescence was further reduced to 36±14% in the presence of 30 mM NaSCN (simulated hit), and to 41±6% in the absence of TatABC, verifying the Δψ- and Tat-dependence of the fluorescence signal (Fig 4D).

The Local HTS

Preliminary HTS testing and optimization, initial small test screens, and a HTS of 51,600 diverse synthetic compounds were performed in the laboratory of one of us (James Sacchet-tini). A sample 384-well plate from this local HTS is shown in Fig 5A. The edge columns contain DMSO (--; negative control) and 30 mM NaSCN (+; positive control). Compounds were tested at 5 or 20 μM. In this HTS, all plates were scanned for both cell growth (A500) and mCherry fluorescence (Fig 5A and 5B). The control wells on each plate were used to calculate the Z'-factor [36] for each plate, which provides an assessment of the performance of the assay on each plate. The average Z'-factor was 0.74±0.09 (Fig 5C; n = 162 plates), indicating a robust HTS assay. Some edge effects were observed (e.g., see Fig 5B), likely from uneven aeration or heating across the plate during the growth incubation period, but these did not interfere with hit calling.

Three categories of non-baseline outputs were identified. The first was "low cell density", the expected signature for growth inhibitors (77 compounds, 0.15% of total). The second category was "high fluorescence and unchanged cell density", which was expected for fluorescent compounds, compounds that enhanced Tat translocation, compounds that increased transcription of the spTorA-mCherry-SsrA mRNA, and compounds that inhibited the ClpXP/ClpAP protease system that recognizes the SsrA tag (208 compounds, 0.41% of total). The third category was "low fluorescence and unchanged cell density", the expected signature for true Tat inhibitors. Compounds exhibiting this signature were considered "hits" (249 compounds, 0.48% of total).

Hits were defined as having a ≥ 20% decrease in mCherry fluorescence, compared with the NaSCN control (100%). The first 12,800 compounds (plates 1–40) were screened using 5 μM of each test compound, yielding a hit rate of 0.016%. This was considered a low hit rate, so the remaining compounds in the library (38,800 compounds, plates 41–162) were assayed at 20 μM, increasing the hit rate to 0.63%. The median fluorescence decrease for hits was 65% (Fig 5D). The 249 hits were re-assayed via dose response (Fig 6), which yielded 78 surviving compounds.

The Broad Institute Probe Development Center (BIPDeC) HTS

The validated 384-well HTS assay was transferred from the Texas A&M Health Science Center to the BIPDeC in order to screen the NIH’s Molecular Library Small Molecular Repository (MLSMR) collection of compounds. Approximately 20% of the compounds in the local chemical library were in common with the MLSMR collection at the time of screening. The HTS assay was adapted to run on the Broad’s high throughput screening system, which required further miniaturization to run in a 1536-well format. To make the primary assay run more efficiently, only the mCherry fluorescence was read, compared to the dual read done for the 384-well assay. From assay development and adaptation experiments, it was determined that glucose addition after the 8 h induction period followed by an overnight incubation at 4°C yielded a better signal-to-background ratio. The assay was validated using the MLSMR
validation set, a small, ~2,000 compound collection composed of known bioactive compounds. The validation run showed strong statistics with an average signal-to-background ratio of 12.9, and an average Z’-factor [36] of 0.86 (data not shown).

Following validation, 337,881 compounds from the MLSMR collection were screened at 10 μM in duplicate using the adapted primary assay (Fig 7A). Tat translocation yield was assessed by the intensity of mCherry fluorescence. Raw fluorescence values were normalized to the average negative (DMSO only) and positive (30 mM NaSCN) controls on each plate. The average Z’-factor was 0.44±0.23 (Fig 7B; n = 538 plates). A mean activity score was calculated...
by averaging the fluorescence decrease observed for the two replicates of each test compound. Active compounds were defined as those compounds with a mean activity score \( C_{50} \geq 50 \) (50% reduction in fluorescence, normalized to the NaSCN and DMSO controls). According to this definition, 123 compounds were active (0.04% of the total screened). An additional 1,263 compounds were labeled as inconclusive, defined as those for which 1 of the 2 replicates had an activity score \( C_{50} \). According to this definition, 1,263 compounds were labeled as inconclusive, defined as those for which 1 of the 2 replicates had an activity score \( C_{50} \). According to this definition, 1,263 compounds were labeled as inconclusive, defined as those for which 1 of the 2 replicates had an activity score \( C_{50} \). According to this definition, 1,263 compounds were labeled as inconclusive, defined as those for which 1 of the 2 replicates had an activity score \( C_{50} \).

The active and inconclusive compounds were then reviewed for chemical intractability, and any compounds determined to be unsuitable for follow-up chemistry were removed from consideration. From this analysis, 1,256 compounds were reordered from the MLSMR for retesting with the primary assay at various concentrations. Of these compounds, 48 yielded an \( IC_{50} < 20 \mu M \) (PubChem BioAssay AID 504941 and 651752). The 1,256 compounds were also tested in a counter assay to identify non-specific bacterial inhibitors, which would show false positive responses in the primary assay. Bacterial viability was assayed using the Bact-TiterGlo (Promega) reagent using the same conditions as the primary assay, except without the addition of induction reagents. From this analysis, 309 compounds exhibited \( > 20\% \) inhibition of bacterial growth (PubChem BioAssays AID 504843 and 651750). Based on the retest, counter-assay and a chemical suitability analysis, 35 potential inhibitors of Tat translocation...
were identified. These compounds were sourced from dry powders for additional retesting and secondary analysis.

Secondary Screening: *In Vitro* Tat Transport Assays

Hits from the primary screen could include false positives for a variety of reasons. Hit compound effects on the sPtorA-mCherry-SsrA reporter that would result in a reduced mCherry fluorescence signal include: i) a folding deficiency (i.e., which does not allow maturation of the mCherry fluorophore); ii) inhibition of transcription or translation; and iii) increased SsrA-dependent degradation (i.e., degradation instead of transport). In addition, Tat-dependent transport requires a $\Delta \psi$ [7]. Therefore, compounds that inhibit PMF generation would be indirect inhibitors of Tat-dependent transport. In contrast, our goal was to identify molecules that inhibited Tat transport by directly binding to Tat proteins. Additional screens were therefore required to verify whether hit compounds interacted specifically with Tat proteins.

To directly test for inhibition of Tat transport, a gel-based *in vitro* Tat transport assay was performed using pre-SufI, an authentic Tat precursor protein [7]. In short, this assay consists of incubating a Tat substrate and a $\Delta \psi$-generating energy source with inverted membrane vesicles (IMVs) containing overproduced TatABC, digesting remaining external protein with a protease, and then analyzing via SDS-PAGE. This assay was run twice using NADH and ATP (if warranted) as energy sources to generate the necessary $\Delta \psi$. NADH generates a $\Delta \psi$ using respiratory proteins (i.e., the NADH dehydrogenase and cytochrome $b_6$ ubiquinol oxidase complexes [35]) and ATP generates a $\Delta \psi$ by reversal of ATP synthase [37]. A true Tat inhibitor
would survive both assays. In contrast, a respiration inhibitor is expected to reduce Tat transport when only one of the two energy sources is used (except for an ionophore).

The criterion for surviving the in vitro Tat transport assays was visible inhibition of Tat transport. Of the 78 compounds surviving the local HTS assay, 7 compounds (S2A–S2G Fig) survived the in vitro Tat transport assay with NADH (Fig 8A). Of these 7 compounds, 6 survived the ATP-dependent Tat transport assay (Fig 8B). Based on its elimination by the ATP-dependent assay, compound 55JS (N-(4,7-Dioxo-4,7-dihydro-2,1,3-benzoxadiazol-5-yl)acetamide) appears to affect some step of aerobic respiration between NADH and O2. Since this compound is a quinone (Fig 8C), a likely possibility is that it interacts with the quinone binding site on NADH dehydrogenase [38,39].

Of the 35 compounds surviving the BIPDeC’s HTS assay, bacterial growth assay and chemical evaluation, 2 compounds (S2H and S2I Fig) survived the NADH- and ATP-dependent Tat transport assays (Fig 9).

Secondary Screening: Δψ Assay

Hit compounds surviving the in vitro Tat transport assay screens could be general Δψ inhibitors (ionophores), as both NADH and ATP generate the Δψ necessary for Tat transport. Since our current assay to measure Δψ requires ~20 times more test compound than the Tat transport assays, we reserved this assay for last. The presence of a Δψ was determined by measuring oxonol VI fluorescence [7]. For all 8 hit compounds that survived initial secondary screening, we tested their dose dependent effect on the Δψ, on NADH-dependent in vitro Tat transport efficiency, and on the fluorescence signal recovered from our primary HTS assay (live cell assay). An example of such an analysis is shown in S3 Fig. The IC50’s calculated from these data indicate that all surviving hit compounds, except compound 18NIH, collapse the Δψ (Table 1), and this explains their ability to inhibit Tat transport. Initially, compound 18NIH (Broad Institute ID: BRD-A27765931-001-04-0) yielded promising results, as it did not collapse the Δψ across IMVs, and yet it did inhibit in vitro Tat transport during early trials (S4 Fig). However, these results could not be reproduced consistently. Out of 22 independent assays by three different people, compound 18NIH inhibited Tat transport 12 times. The conflicting results seem more likely to arise from differences in IMV preparations rather than decomposition of or impurities in the samples of compound 18NIH.

Effect of Pseudomonas aeruginosa Tat Inhibitors on E. coli Tat Transport

The two compounds N-phenylmaleimide and Bay 11–7082 were recently identified as inhibitors of the Pseudomonas aeruginosa Tat machinery as a result of high throughput screening [30]. We tested the effect of both compounds on transport by the E. coli Tat system. Both N-phenylmaleimide and Bay 11–7082 inhibited E. coli growth under Tat++ conditions (S5 Fig). Both compounds also inhibited synthesis of spTorA-mCherry-SsrA, though this appears to be a consequence of growth inhibition. Most importantly, neither compound affected in vitro E. coli Tat transport, and thus, we conclude that these compounds are not E. coli Tat transport inhibitors (S5 Fig).

Both N-phenylmaleimide and Bay 11–7082 chemically react with cysteines [40]. There is only one cysteine found in the P. aeruginosa Tat machinery, C208 of TatC. However, this residue is buried within the TatC structure [15], and thus, it seems unlikely that it can be modified by these reagents. Alternatively, if these reagents inhibit P. aeruginosa Tat transport by non-covalent binding interactions with Tat proteins, our data indicate that such interactions are not conserved between E. coli and P. aeruginosa.
A high throughput screening approach suitable for identifying small molecule inhibitors of the *E. coli* Tat protein transport system was developed. The strengths of the reported approach include: 1) an average Z'-factor > 0.7 (under the right screening conditions), which indicates a robust HTS assay that need not be run in duplicate [36]; 2) a live cell primary HTS, enabling early assessment of *in vivo* activity; 3) a hit rate ~0.5%, indicating selectivity; and 4) a series

Fig 8. Effect of Hits from the Local HTS on *In Vitro* Tat Transport. (A) Tat transport assays of pre-SufI using NADH to generate a Δψ. Inverted membrane vesicles (IMVs; λ_{280} = 5.0), the fluorescent substrate pre-SufI-lacC_{ATCC655}(90 nM), and NADH (4 mM) were incubated at 37°C for 30 min with DMSO (control) or with hit compound (20 μM). Samples were treated with the protease proteinase K, run on SDS-PAGE, and analyzed by in-gel fluorescence imaging. Assays were run in duplicate. Band intensity corresponds to the amount of protein transported into the IMV lumen. The following 7 compounds survived this screen: 1JS, 51JS, 55JS, 111JS, 181JS, 202JS, and 140JS (boxed in red). (B) Tat transport assays of pre-SufI using ATP to generate a Δψ. All 7 compounds surviving the screen in (A) were tested using a Tat transport assay performed identically to those in (A) except that ATP (1 mM) was used in place of NADH. Compound 55JS was eliminated by this assay—the other 6 compounds survived (boxed in red). (C) Chemical structure of compound 55JS, N-(4,7-Dioxo-4,7-dihydro-2,1,3-benzoxadiazol-5-yl)acetamide. The quinone structure suggests NADH dehydrogenase as a possible target, leading to inhibition of Tat transport when using NADH as the energy source (A), but not when ATP is used (B).

doi:10.1371/journal.pone.0149659.g008

Discussion

A high throughput screening approach suitable for identifying small molecule inhibitors of the *E. coli* Tat protein transport system was developed. The strengths of the reported approach include: 1) an average Z'-factor > 0.7 (under the right screening conditions), which indicates a robust HTS assay that need not be run in duplicate [36]; 2) a live cell primary HTS, enabling early assessment of *in vivo* activity; 3) a hit rate ≤ ~0.5%, indicating selectivity; and 4) a series
of *in vitro* follow-up screens/assays that enable direct evaluation of hit activity against the target system. Additional assays are available that would enable further *in vitro* characterization of compound binding properties and the site of action [7,41]. Unfortunately, despite screening ~380,000 compounds, no inhibitors that bind directly to Tat proteins were identified. Based on the *in vitro* follow-up assays, 7 hit compounds inhibit Tat transport by collapsing the Δψ, one compound (55NS) inhibits Δψ generation by NADH (possibly by inhibiting NADH dehydrogenase), and one compound (18NIH) yielded irreproducible results. In addition, the two

---

**Fig 9. Effect of Hits from the BIPDeC HTS on *In Vitro* Tat Transport.** (A) & (B) Tat transport assays as in (A) and (B) of Fig 7, respectively, using hit compounds from the BIPDeC HTS. Hit compound concentrations of 100 µM were used to maximize Tat transport inhibition, as the effects of a lower concentration (20 µM) were not very pronounced (data not shown). Compounds 18NIH and 21NIH survived the NADH-dependent assay (A) and were tested in the ATP-dependent assay (B). Both of these compounds survived the ATP-dependent assay. Surviving compounds at each stage are boxed in red.

doi:10.1371/journal.pone.0149659.g009
compounds previously identified as *P. aeruginosa* Tat machinery inhibitors were shown not to be *E. coli* Tat inhibitors. Since the proton motive force drives a wide range of crucial processes, *E. coli* are not expected to divide and multiply if they cannot maintain a membrane potential across the cytoplasmic membrane. How, then, did 7 hits survive the HTS and *in vivo* growth screen, only to be eliminated in follow-up assays as compounds that collapse the Δψ? Similarly, why do the ionophores nigericin and valinomycin inhibit Tat transport *in vitro* [7] but not *in vivo* (Fig 4A)? Efflux pumps, poor cell permeability of the cell envelope, or reduced efficacy due to binding interactions that reduce the compound’s concentration in the lipid can certainly contribute to these results. However, if these are the only explanations, it is not immediately clear how compounds can reduce Tat transport (i.e., decrease total mCherry fluorescence) by disrupting the membrane potential and yet not affect cell growth. The answer may lie in the magnitude of the Δψ required to support Tat transport. We earlier reported that *in vitro* E. coli Tat transport requires a relatively large Δψ, though it is not necessary for the duration of the transport cycle [7]. Consequently, it is possible that *in vivo* Tat transport is substantially reduced when the Δψ is minimally decreased, and yet growth is largely unaffected since it is not as sensitive to the magnitude of the Δψ.

Compound 18NIH (triclosan; PubChem CID 5564) has antibacterial and antifungal activities and is found in many commercial products, including soaps, toothpaste, hand and mouth washes, toys, bedding, and trash bags [42]. Surgical scrubbing with triclosan is effective against bacterial infections in a hospital setting [43]. Though triclosan has multiple cellular targets, the primary (high *K_D*) target is the bacterial enzyme enoyl-acyl carrier protein reductase (ENR; gene *FabI*), an enzyme required for fatty acid synthesis [44]. Triclosan is bacteriostatic at low concentrations. At higher concentrations, it is bactericidal and it promotes tumors in liver [45,46]. We conclude that the inconsistent effects of triclosan on *in vitro* Tat transport arise from binding interactions with other target enzymes.

### Table 1. IC_{50}'s for Hits Surviving the In Vitro Tat Transport Assays.

| Compound ID | IC_{50} (μM) (Live Cell Assay) | IC_{50} (μM) (Tat Transport) | IC_{50} (μM) (Δψ) |
|-------------|-------------------------------|-------------------------------|-------------------|
| 1JS         | 6                             | 3                             | 1                 |
| 51JS        | 20                            | 12                            | 8                 |
| 111JS       | 31                            | 0.7                           | 0.1               |
| 181JS       | 20                            | 1                             | 0.4               |
| 202JS       | 5                             | 11                            | 3                 |
| 140JS       | 14                            | 2                             | 1                 |
| 18NIH       | 2                             | IC^a                          | > 100^b           |
| 21NIH       | 13                            | 50                            | 4                 |

The IC_{50}'s obtained for the mCherry fluorescence intensity during *in vivo* cell growth (column 2), for the efficiency of NADH-dependent *in vitro* Tat transport (column 3), and for the electrical field gradient (column 4) are tabulated for hit compounds that survived both *in vitro* Tat transport assays (see Fig 10). Sample results and assay details are provided in S3 Fig. Note that the membrane concentration in the *in vitro* transport assays (A_{280} = 5) was 10-fold higher than in the Δψ assays (A_{280} = 0.5), and hence, the IC_{50}'s are higher in the former assays since the compounds must partition into the membrane bilayer. Transport assays require high IMV concentrations in order to observe sufficient transport on gels. Δψ assays require low IMV concentrations in order to more accurately detect the maximum Δψ before the dissolved oxygen is consumed [7].

^aInconclusive (IC) due to lack of reproducible inhibition of Tat transport (S4A Fig).
^bNotably, 18NIH increased the duration of the Δψ (S4B and S4C Fig).

doi:10.1371/journal.pone.0149659.t001
High throughput screening provides the opportunity to efficiently and cost-effectively test a large number of diverse small molecules such that at least a few lead compounds that inhibit the target pathway can be identified even when the “hit” rate is particularly low [47]. The identification of compounds that bind to transmembrane regions has been especially difficult [48–50]. Though TatA and TatB have extramembraneous cytoplasmic domains, these are relatively small and may not have stable secondary and tertiary structures [51]. TatC is predominantly transmembrane, with relatively small extramembrane loops [15,18]. In addition, the signal peptide appears to bind deep within the membrane-spanning protein of the TatBC complex, rather than at the cytoplasmic surface [52,53]. Thus, the Tat machinery appears to have little hydrophilic surface area and it is unclear how much of this is important for binding interactions or conformational changes. These reasons may at least partially explain the difficulty with identifying inhibitors of the Tat machinery. Chemical libraries designed to target transmembrane regions may be better suited for identifying Tat machinery drug leads. Alternatively, the

Fig 10. Summary of the HTS’s and Hit Analysis by Follow-up Screens. Surviving and eliminated compounds from the local (left) and BIPDeC (right) HTS’s are denoted by black and red numbers, respectively. The number of eliminated compounds at each step is shown to the right of the arrows and the number of surviving compounds are shown on the left in bold. Active (123) and inconclusive (1263*) compounds after the primary BIPDeC HTS were evaluated for chemical intractability and then retested in dose response and cell growth assays.

doi:10.1371/journal.pone.0149659.g010
recent X-ray structure of TatC [15,18] suggests that identification of the signal peptide binding site is forthcoming, which would enable structure-based drug design.

Materials and Methods

Bacterial Strains, Plasmids and Growth Conditions

Plasmids and Tat proteins were as follows. Plasmids pTorA-GFP and pET25-SufI [7] encode spTorA-GFP-H6 and pre-SufI-H6, respectively, both of which contain C-terminal 6xHis tags. Plasmid pSufI-IAC [54] encodes a single-cysteine derivative of pre-SufI-H6, and was generated by mutations C17I and C295A and the addition of a cysteine immediately following the 6xHis tag (C497). Plasmids pTorA-mCherry-H6 and pTorA-mCherry-SsrA are derivatives of plasmid pTorA-GFP [7], and encode spTorA-mCherry-H6 and spTorA-mCherry-SsrA (S1 Fig), respectively, under the control of the arabinose inducible promoter of pBAD24 (ColE1 origin). These proteins consist of the TorA (a native Tat substrate) signal peptide (spTorA), mCherry (a fluorescent cargo protein) and either a 6xHis tag or SsrA-tag (which promotes protein degradation in the cytoplasm by the Clp protease system) [31]. Plasmid pTorA-GFP-SsrA encodes the protein spTorA-GFP-SsrA, which is identical to the TorA-GFP-SsrA protein reported earlier [31], except that the host vector is the same as for pTorA-mCherry-SsrA described above. Plasmid pTatABC-Duet1 was constructed by cloning the NcoI-SalI insert from pTatABC [55] into pACYC-Duet1 (p15A origin). This plasmid encodes the E. coli TatA, TatB and TatC proteins under the control of T7 promoter, and can co-exist with plasmids pTorA-mCherry-H6, pTorA-mCherry-SsrA, or pTorA-GFP-SsrA. All protein coding regions were confirmed by DNA sequencing. The three different strain backgrounds used are: ΔTat (MC4100ΔTatABCDE); Tat⁺ [MC4100(DE3)]; and Tat⁺⁺ [MC4100(DE3) with pTatABC-Duet1]. E. coli strains MC4100ΔTatABCDE and MC4100(DE3) were a gift of Tracy Palmer (University of Dundee), and have been described earlier [56,57].

E. coli strains MC4100(DE3) and JM109 [55,57,58] were used for the HTS and for cloning purposes, respectively. E. coli cultures were grown using Luria-Bertani (LB) media (Growcells, Irvine, CA 92618, USA) and were supplemented with ampicillin (Ap, 100 μg/mL; Sigma-Aldrich Corporation, MO, USA), chloramphenicol (Cm, 34 μg/mL) (USB Corporation, OH, USA), arabinose (Sigma-Aldrich Corporation, MO, USA), and IPTG (G-Biosciences, MO, USA) as required for growth and induction, unless otherwise indicated.

Isolation of Arabinose-Resistant Strains

MC4100 is an araD mutant strain, and L-arabinose inhibits its growth. Suppressor mutations are readily obtained when this strain is grown with arabinose, and these typically yield strains generating variable levels of overproduced proteins [59]. Therefore, arabinose-resistant Tat⁺ and Tat⁺⁺ strains were generated, as described below, to ensure more consistency in protein overproduction. An arabinose-resistant ΔTat strain was not generated.

E. coli strains MC4100(DE3) (pTatABC-Duet1, pTorA-mCherry-H6) and MC4100(DE3) (pTatABC-Duet1, pTorA-mCherry-SsrA) were grown in 20 mL LB media supplemented with Cm and Ap, and shaken (250 rpm) at 37°C until A₅₀₀ ≈ 0.5. The cultures were then supplemented with 100 mM arabinose, incubated overnight (~15 hours) under the same conditions, and then serially diluted and plated on LB-agar supplemented with Cm and Ap. After incubating the plates overnight at 37°C, 6 colonies from each strain were tested for the production and periplasmic localization of spTorA-mCherry-H6 and spTorA-mCherry-SsrA by in situ gel-fluorescence using a phosphorimager Model FX. For each protein, all colonies exhibited similar production and periplasmic localization patterns (data not shown). This approach yielded strains that overproduce spTorA-mCherry-H6 or spTorA-mCherry-SsrA in the Tat⁺⁺ background.
To obtain the Tat+ strain, a plasmid-free version of arabionose-resistant MC4100(DE3) (pTatABC-Duet1, pTorA-mCherry-SsrA) was obtained as follows. A 10 mL LB culture was grown overnight (37°C), and then repeatedly (5X) subcultured into fresh 10 mL LB media at a 1:100 ratio every 24 h. The final culture was serially diluted and plated on LB-agar plates and incubated overnight at 37°C. Colonies were replica-plated on LB-agar plates lacking antibiotics and plates supplemented with Ap or Cm, respectively. Six antibiotic-insensitive colonies were chosen, and confirmed to be arabionose-resistant by growth on plates with 100 mM arabinoose. One of these was chosen as the Tat+ strain, which was transformed with pTorA-mCherry-SsrA to generate a strain that overproduces spTorA-mCherry-SsrA in the Tat+ background.

Cell Fractionation

The cellular location of mCherry proteins was determined by cell fractionation. Cells were grown overnight in 2 mL LB broth supplemented with appropriate antibiotics at 37°C. These cultures were diluted 1:50 in 2 mL of fresh media, and growth was continued at 37°C with shaking (200 rpm) until $A_{500} \approx 1.0$. Protein production was then induced by arabinoose addition, and cultures were grown at 25°C for 8 h. Cells (1 mL, $A_{500} = 1.0$) were fractionated as described [60]. Both cytoplasmic and periplasmic fractions were suspended in a final volume of 100 μL in 1x sample buffer (10% glycerol, 2% SDS, 0.01% bromophenol blue, 1.25% β-mercaptoethanol, 60 mM Tris-Cl, pH 6.8), and a 10 μL fraction was analyzed by SDS-PAGE and detected by in situ gel-fluorescence using a phosphorimager Model FX (Bio-Rad Laboratories) [7], or by Western blot analysis.

Imaging mCherry Localization

Imaging of cells expressing various mCherry precursors was performed similar to the approach described earlier for spTorA-GFP [60]. Strains were grown in 1 mL LB media supplemented with appropriate antibiotics at 37°C, 250 rpm for 6 h. mCherry Tat precursors were induced with 2 mM arabinoose and cultures were incubated overnight (~15 h, 25°C, 250 rpm). Cells were harvested (4,000 g for 10 min), and incubated in fresh LB media (2 mL) with antibiotics but no arabinoose for an additional 5 h. The undiluted culture (5 μL) was place on a glass coverslip, and covered with a 2 mm thick square of agarose gel (prepared in 17 mM NaCl, 10 mM Tris, pH 7.0) to immediately immobilize the cells. Cells were imaged with spinning disk confocal microscopy (Yokogawa) using 561 nm excitation on a Zeiss Axiovert 200M microscope equipped with a 1.46 NA 100X oil-immersion objective (Zeiss alpha PlanApochromat) and a 512x512 EMCCD camera (Andor) [61].

Assays

Isolation of inverted membrane vesicles (IMVs), Western blot analyses and purification of pre-SufI-IAC were performed as described previously [7,62]. Western blots were performed using rabbit anti-mCherry antibodies (1:10,000 dilution) in the presence of 0.1% Triton X-100 and 0.1% Tween 20. The pre-SufI-IAC protein was labeled with Atto565 maleimide, and the resultant fluorescent protein, pre-SufI-IACAtto565, was used as a substrate for the in vitro Tat transport assays ($A_{280} = 5.0$), as described previously [7,62]. The presence of a Δψ was determined by measuring oxonol VI fluorescence in presence of Tat+ IMVs ($A_{280} = 0.5$), as described previously [7], except that the translocation buffer lacked BSA. Steady-state fluorescence spectra and fluorescence intensities of whole cells producing mCherry proteins were determined with an SLM-8100 spectrofluorometer.
HTS for 384-Well Plates

A single colony of *E. coli* strain MC4100(DE3) (pTatABC-DUET1, pTorA-mCherry-SsrA) was inoculated into a 100 mL LB culture supplemented with Ap and Cm and grown at 37°C with shaking (250 rpm) overnight. Cells were harvested by centrifugation at 4,000g for 10 min at room temperature (RT), suspended in 10 mL fresh LB broth supplemented with Ap and Cm, and the optical density (A$_{500}$) was determined. Simultaneously, 700 mL LB supplemented with 100 mM arabinose, 2 mM IPTG, 100 μg/mL Ap and 68 μg/mL Cm was filter-sterilized (0.22 μm), and then divided into 200 mL (A) and 500 mL (B) portions. Sterile NaSCN (30 mM final; 1.5 mL of 4 M NaSCN) was added to portion A, and an equal ratio of sterile water was added to portion B (3.75 mL). Media and cells were transferred to the HTS facility on ice.

A CyBi-Well vario pipetting workstation (CyBio, Jena, Germany) was used to dispense library compounds and cultures. Library compounds (1 μL) solubilized in DMSO were added to 384-well black, clear-bottomed plates (Greiner Bio-one, Germany) in columns 3 to 22 (320 wells/plate). For controls, DMSO (1 μL) was added to each well in columns 1, 2, 22 and 23, to achieve DMSO uniformity across the plate. Both portions of LB media were inoculated with *E. coli* MC4100(DE3) (pTatABC-DUET1, pTorA-mCherry-SsrA) from the concentrated stock to a final A$_{500}$ = 0.15. The media with 30 mM NaSCN (positive control, or simulated hit) was dispensed into each well of columns 1 and 24 (49 μL each). An equivalent volume of media without NaSCN was dispensed into each well of columns 2 to 23. Columns 2 and 23 lacked NaSCN and test compounds and served as negative controls. The first 12,800 compounds were screened at 5 μM (plates 1–40), and the remaining 38,800 compounds were screened at 20 μM (plates 41–162).

The plates containing cells and dispersed test compounds were grown with shaking (200 rpm) at 25°C for 8 h. Plates were individually mounted, not stacked, on a hollow plastic platform, allowing adequate air circulation. Following the 8 h incubation, plates were transferred to 4°C for 16 h. Each plate was covered with an empty plate to prevent condensation on the lid. The overnight incubation was found to improve the signal-to-background ratio. Following the incubation, plates were read using a BMG Polarstar Omega plate reader (BMG Labtech, Ortenberg, Germany) to determine optical densities (A$_{500}$) and mCherry fluorescence intensities (EX = 584 nm, EM = 620 nm).

HTS for 1536-Well Plates

This assay was performed at the Broad Institute Probe Development Center (BIPDeC; Cambridge, MA), a comprehensive screening center and member of the Molecular Libraries Probe Production Centers Network (MLPCN). The original 384-well assay was transferred to the BIPDeC, where the assay was miniaturized and optimized to run in 1536-well plates. Briefly, an *E. coli* MC4100(DE3) (pTatABC-DUET1, pTorA-mCherry-SsrA) culture was grown overnight in liquid LB broth supplemented with Ap and Cm. The culture was harvested, suspended in 10 mL fresh media, and placed on ice. The optical density of the culture was determined, and then diluted to A$_{500}$ = 0.15 with ice cold LB broth supplemented with 100 mM arabinose, 2 mM IPTG, 100 μg/mL Ap and 68 μg/mL Cm. Black, solid bottom, 1536-well assay plates (Aurora (Brooks), Chelmsford, MA) were previously prepared with compounds in DMSO (7.5 nL) by acoustic transfer (Echo555, LabCyte, Sunnyvale, CA). Positive (LB broth supplemented with 30 mM NaSCN) and negative (LB broth supplemented with an equivalent volume of water instead of NaSCN) controls were added (100 nL) to 256 designated control wells. Assay plates were loaded into an integrated high throughput screening system (HighRes Biosolutions, Woburn, MA), which performed all the assay steps. The assay was initiated by the addition of 7.5 μL of the induced culture, and then incubated for 8 h at 30°C with shaking at 200 rpm.
Plates were removed from the incubator, 2.5 μL of 5% glucose was added to each well, and the plates were returned to the incubator for 4 h. Plates were then incubated at 4°C overnight. At the completion of the assay, the plates were read on an Envision (PerkinElmer, Waltham, MA) plate reader to determine the fluorescence intensity. The data were analyzed using Genedata Assay Analyzer (Lexington, MA), and submitted to PubChem. Following analysis, compounds from the primary screen were ordered and retested at dose response. Compounds were spotted on assay plates as previously described, at 8 different concentrations ranging from 40 μM to 0.3 μM, in 2-fold dilutions. These same compounds were also tested in a counter assay designed to identify non-specific bacterial growth inhibitors, which produce false positive results in the primary assay. E. coli MC4100(DE3) (pTatABC-Duet1, pTorA-mCherry-SsrA) was cultured and harvested as done for the primary assay, and then inoculated into fresh LB supplemented only with Ap and Cm. Compounds were spotted in dose response format on white, solid-bottomed assay plates (Aurora (Brooks), Chelmsford, MA). Kanamycin (40 μg/mL) was added to 144 positive control wells. Cultures were incubated with compounds for 8 h, and then assessed for viability with Bac-TiterGlo (Promega, Madison, WI). Luminescence was detected with an Envision plate reader. Data from the dose response experiments were analyzed using Genedata Assay Analyzer and Condeseo, and submitted to PubChem.

Characteristics of Chemical Libraries

The local library was constructed to ensure diversity among the compounds, guaranteeing that no pair of compounds had a Tanimoto similarity score greater than 0.7. This approach minimizes the bias of many existing libraries, which often contain many variations of common scaffolds. This diversity library was designed by combining structures from catalogs of small molecules from multiple commercial vendors totaling over 3 million compounds, and selecting a diverse and representative subset using a clustering algorithm. The compounds were first filtered by Lipinski’s rules to remove non-drug-like compounds, and then compounds with reactive chemotypes or those predicted to be promiscuous aggregators were removed. At the time of the primary HTS assay, the local library consisted of 51,600 compounds.

The MLSMR collection of compounds is described at: http://mli.nih.gov/mli/compound-repository/mlsmr-compounds/. At the time of our primary screening, the MLSMR collection of compounds consisted of 337,881 compounds.

Supporting Information

S1 Fig. Restriction Map and Amino Acid Sequence of spTorA-mCherry-SsrA. The amino acid sequence of spTorA, mCherry and the SsrA tag are highlighted in yellow, red and green, respectively. The linker sequence between spTorA and mCherry is highlighted in blue. The parent plasmid was pTorA-GFP [7]. For pTorA-mCherry-H6, the SsrA-tag was replaced with a 6xHis-tag. For pTorA-GFP-SsrA, the mCherry protein was replaced with GFP.

(TIFF)

S2 Fig. Chemical Structures of Hit Compounds that Survived the In Vitro NADH-Dependent Tat Transport Assays. (A) [(2-bromophenyl)hydrazono]malononitrile (PubChem CID 23273954), (B) 1-chloro-2,4-dinitronaphthalene (PubChem CID 16987), (C) N-(4,7-dioxo-2,1,3-benzoxadiazol-5-yl)acetamide (PubChem CID 610143), (D) 1-[[2,3,5,6-tetrafluoropyridin-4-yl]amino]-3-[3-(trifluoromethyl)phenyl]thiourea (PubChem CID 11158), (E) 1-(5-nitro-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea (PubChem CID 1825994), (F) 4-nitro-2-thiophen-2-ylphenol (PubChem CID 7131469), (G) 5-[3-(trifluoromethyl)phenyl]isoquinoline (PubChem CID 140458), (H) 5-Chloro-2-(2,4-dichlorophenoxy)
phenol (18^NIH; triclosan; PubChem CID 5564), and (I) 5-[(3,5-dichlorophenyl)methyl]-4,6-dihydrotriazolo[1,5-a][1,4]benzodiazepine-6-carbonitrile. (NIH21; PubChem CID 44825859).

**S3 Fig. IC50’s for Hit Compound 18^IS.** These data illustrate how the IC50’s summarized in Table 1 were obtained. (A) The total cellular mCherry fluorescence (live cell assay; n = 1), (B) the in vitro NADH-dependent Tat transport efficiency of pre-SufI (n = 1), and (C) the maximum transmembrane electrical potential gradient (n = 1) were measured for a range of concentrations of compound 18^IS (S2E Fig). (D) SDS-PAGE gel showing in-gel fluorescence data used in (B). For (A), cells expressing spTorA-mCherry-SsrA were grown under Tat++ conditions in a 384-well plate in the presence of 0, 0.08, 0.15, 0.3, 0.63, 1.25, 2.5, 5, 10, 20, or 40 μM compound 18^IS, as described for the HTS assay (see Methods). For (B) and (C), IMVs were incubated with the same concentrations of compound 18^IS prior to initiation of Tat transport and Δψ generation by the addition of NADH, as described previously [7]. The red curves are best-fits using y = d + (100-d)/(1+(x/IC50)^b), where b is a slope factor and d is the high concentration asymptote [64].

**S4 Fig. Characterization of Compound 18^NIH.** (A) Effect of compound 18^NIH (S2H Fig) on in vitro Tat transport of pre-SufI using NADH (4 mM) to generate a Δψ. Out of 22 independent assays by three different people, compound 18^NIH inhibited Tat transport 12 times. Shown here are 4 representative assays, the top 2 of which show inhibited transport. For calibration of transport efficiency, 20 and 40% of the pre-SufI added to the reaction is shown in the leftmost lanes (Std). A minus NADH control (-) is also shown. (B & C) Effect of compound 18^NIH on the magnitude and duration of the Δψ across the IMV membrane. The top panel (B) demonstrates that compound 18^NIH affected both the magnitude and the duration of the Δψ for the assayed IMV preparation. The bottom panel (C) summarizes the effect of compound 18^NIH on the duration of the Δψ, the magnitude of the Δψ and in vitro Tat transport (n = 1 for the Δψ values and n = 3 for in vitro Tat transport using two IMV preparations). These data suggest that when compound 18^NIH does inhibit Tat transport, it does NOT do so by collapsing the Δψ. However, since compound 18^NIH does NOT ALWAYS inhibit Tat transport (see A), direct binding to (and inhibition of) the Tat machinery does not appear to be the dominating interaction of the compound.

**S5 Fig. Effect of P. aeruginosa Tat Inhibitors on E. coli Cell Growth and Tat Transport.** The concentration-dependent effects of Bay 11–7082 (A) and N-phenylmaleimide (B) on bacterial growth (black) and in vivo Tat transport of spTorA-mCherry-SsrA (red) was determined under Tat++ conditions (top). An overnight culture of MC4100(DE3) (pTorA-mCherry-SsrA, pTatABC-Duet1) was diluted 1:50 in 10 mL fresh LB broth with appropriate antibiotics and dispensed (2 mL) into 5 tubes, and growth was continued at 37°C with shaking at 200 rpm until A500 ≈ 0.5. The indicated concentrations of the two compounds were added, and the expression of spTorA-mCherry-SsrA and TatABC were induced. Cultures were grown for another 8 h at 25°C. Cell growth was assayed by A500, and cells (1 mL, A500 = 1.0) were fractionated into cytoplasmic (C) and periplasmic (P) fractions as described [60]. Transport of spTorA-mCherry-SsrA was assayed by in-gel fluorescence of mCherry (upper gels) and Western blot analyses (middle gels). The quantified in vivo transport of spTorA-mCherry-SsrA is an average of the in-gel mCherry fluorescence and the Western blot analysis. The mature mCherry-SsrA in the periplasmic fraction of cells grown in the absence of a putative inhibitor was set to 100%. In vitro Tat transport assays in the presence of 2.5 mM DTT (bottom gels) were performed.
with 90 nM pre-SufI and reactions were initiated with NADH [7]. Control assays performed in the absence of NADH are identified (-). In the left set of experiments (I), the putative inhibitors were treated with DTT prior to addition of IMVs and pre-SufI. In the right set of experiments (II), IMVs were pre-incubated with the putative inhibitors prior to addition of pre-SufI and DTT. Transport assays performed with and without DTT (bottom; IMVs pre-incubated with compounds for 5 min prior to Sufl and NADH addition) demonstrate that both DTT reacted and unreacted forms of the two compounds do not inhibit \textit{E. coli} Tat transport.

\section*{Acknowledgments}
We thank T.L. Yahr for pET-SufI and pTatABC; T. Palmer for MC4100(DE3) and MC4100\(\Delta\)TatABCDE; and E. D. Hernandez for teaching UKB how to use the CyBi-Well Vario pipetting workstation. This research was supported by the National Institutes of Health (GM065534 & NS063904 to SMM; U54 HG005032 & R21 NS063904-01 to Molecular Libraries Probe Development Network) and the Welch Foundation grant (A-0015 to JCS).

\section*{Author Contributions}
Conceived and designed the experiments: UKB LV DB WD JCS SMM. Performed the experiments: UKB LV SH NW. Analyzed the data: UKB LV DB SMM. Wrote the paper: UKB LV DB SMM.

\section*{References}
1. Schatz G, Dobberstein B (1996) Common principles of protein translocation across membranes. \textit{Science} 271: 1519–1526. PMID: 8599107
2. Wallin E, von Heijne G (1998) Genome-wide analysis of integral membrane proteins from eubacterial, archaean, and eukaryotic organisms. \textit{Protein Sci} 7: 1029–1038. PMID: 9568909
3. de Keyzer J, van der Does C, Driessen AJ (2003) The bacterial translocase: a dynamic protein channel complex. \textit{Cell Mol Life Sci} 60: 2034–2052. PMID: 14618254
4. Berks BC, Sargent F, Palmer T (2000) The Tat protein export pathway. \textit{Mol Microbiol} 35: 260–274. PMID: 10652088
5. Cline K, Ettinger WF, Theg SM (1992) Protein-specific energy requirements for protein transport across or into thylakoid membranes. Two luminal proteins are transported in the absence of ATP. \textit{J Biol Chem} 267: 2688–2696. PMID: 1733965
6. Mould RM, Robinson C (1991) A proton gradient is required for the transport of two luminal oxygen-evolving proteins across the thylakoid membrane. \textit{J Biol Chem} 266: 12189–12193. PMID: 1648086
7. Bageshwar UK, Musser SM (2007) Two electrical potential-dependent steps are required for transport by the \textit{Escherichia coli} Tat machinery. \textit{J Cell Biol} 179: 87–99. PMID: 17908913
8. Sargent F, Bogschi EG, Stanley NR, Wexler M, Robinson C, Berks BC, et al. (1998) Overlapping functions of components of a bacterial Sec-independent protein export pathway. \textit{EMBO J} 17: 3640–3650. PMID: 9649434
9. Berks BC, Palmer T, Sargent F (2005) Protein targeting by the bacterial twin-arginine translocation (Tat) pathway. \textit{Curr Opin Microbiol} 8: 174–181. PMID: 15802249
10. Palmer T, Sargent F, Berks BC (2005) Export of complex cofactor-containing proteins by the bacterial Tat pathway. \textit{Trends Microbiol} 13: 175–180. PMID: 15817387
11. Yen MR, Tseng YH, Nguyen EH, Wu LF, Saier MH Jr. (2002) Sequence and phylogenetic analyses of the twin-arginine targeting (Tat) protein export system. \textit{Arch Microbiol} 177: 441–450. PMID: 12029389
12. Settles AM, Yonetani A, Baron A, Bush DR, Cline K, Martienssen R, et al. (1997) Sec-independent protein translocation by the maize Hcf106 protein. \textit{Science} 278: 1467–1470. PMID: 9367960
13. Behrendt J, Standar K, Lindenstrauss U, Bruser T (2004) Topological studies on the twin-arginine translocase component TatC. \textit{FEMS Microbiol Lett} 234: 303–308. PMID: 15135537
14. Ki JJ, Kawarasaki Y, Garm J, Harvey BR, Iverson BL, Georgiou G, et al. (2004) A periplasmic fluorescent reporter protein and its application in high-throughput membrane protein topology analysis. J Mol Biol 341: 901–909. PMID: 15282603

15. Rollauer SE, Tarry MJ, Graham JE, Jaaskelainen M, Jager F, Johnson S, et al. (2012) Structure of the TatC core of the twin-arginine protein transport system. Nature 492: 210–214. doi: 10.1038/nature11683 PMID: 23201679

16. Alami M, Luke I, Deitermann S, Eisner G, Koch HG, Brunner J, et al. (2003) Differential interactions between a twin-arginine signal peptide and its translocase in Escherichia coli. Mol Cell 12: 937–946. PMID: 14580344

17. Jack RL, Sargent F, Berks BC, Sawers G, Palmer T (2001) Constitutive expression of Escherichia coli tat genes indicates an important role for the twin-arginine translocase during aerobic and anaerobic growth. J Bacteriol 183: 1801–1804. PMID: 11160116

18. Ramsammy S, Abrol R, Suloway CJ, Clemens WM Jr. (2013) The glove-like structure of the conserved membrane protein TatC provides insight into signal sequence recognition in twin-arginine translocation. Structure 21: 777–788. doi: 10.1016/j.str.2013.03.004 PMID: 23583035

19. Gohike U, Pullan L, McDevitt CA, Porcelli I, de Leeuw E, Palmer T, et al. (2005) The TatA component of the twin-arginine protein transport system forms channel complexes of variable diameter. Proc Natl Acad Sci U S A 102: 10482–10486. PMID: 16027357

20. de Leeuw E, Porcelli I, Sargent F, Palmer T, Berks BC (2001) Membrane interactions and self-association of the TatA and TatB components of the twin-arginine translocation pathway. FEBS Lett 506: 143–148. PMID: 11591389

21. De Buck E, Lammertyn E, Anne J (2008) The importance of the twin-arginine translocation pathway for bacterial virulence. Trends Microbiol 16: 442–453. doi: 10.1016/j.tim.2008.06.004 PMID: 18715784

22. Saint-Joanis B, Demangel C, Jackson M, Brodin P, Marsollier L, Bosshoff H, et al. (2006) Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence. J Bacteriol 188: 6669–6679. PMID: 16952959

23. Wu LF, Ize B, Chanal A, Quentin Y, Fichant G (2000) Bacterial twin-arginine signal peptide-dependent protein translocation pathway: evolution and mechanism. J Mol Microbiol Biotechnol 2: 179–189. PMID: 10939242

24. McDonough JA, Hacker KE, Flores AR, Pavelka MS Jr., Braunstein M (2005) The twin-arginine translocation pathway of Mycobacterium smegmatis is functional and required for the export of mycobacterial beta-lactamases. J Bacteriol 187: 7667–7679. PMID: 16267291

25. Ochsner UA, Snyder A, Vasil AI, Vasil ML (2002) Effects of the twin-arginine translocase on secretion of virulence factors, stress response, and pathogenesis. Proc Natl Acad Sci U S A 99: 8312–8317. PMID: 12034867

26. Pradel N, Ye C, Livrelli V, Xu J, Joly B, Wu LF, et al. (2003) Contribution of the twin arginine translocation system to the virulence of enterohemorrhagic Escherichia coli O157:H7. Infect Immun 71: 4908–4916. PMID: 12933832

27. Stanley NR, Findlay K, Berks BC, Palmer T (2001) Escherichia coli strains blocked in Tat-dependent protein export exhibit pleiotropic defects in the cell envelope. J Bacteriol 183: 139–144. PMID: 11114910

28. Levy SB, Marshall B (2004) Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 10: S122–129. PMID: 15577930

29. Pett W, Lavrov DV (2013) The twin-arginine subunit C in Oscarella: origin, evolution, and potential functional significance. Integ Comp Biol 53: 495–502. doi: 10.1093/icb/ict079 PMID: 23864529

30. Vasil ML, Tomaras AP, Pritchard AE (2012) Identification and evaluation of twin-arginine translocase inhibitors. Antimicrob Agents Chemother 56: 6223–6234. doi: 10.1128/AAC.01575-12 PMID: 23006747

31. DeLisa MP, Samuelson P, Palmer T, Georgiou G (2002) Genetic analysis of the twin arginine translocation pathway in bacteria. J Biol Chem 277: 29825–29831. PMID: 12021272

32. Horwitz AH, Miyada CG, Wilcox G (1984) Functional limits of the araBAD promoter suggest an additional regulatory site for araBAD expression. J Bacteriol 158: 141–147. PMID: 6370954

33. Kin E, Anraku Y (1974) Diphenyl phosphorazidate: a new potent organic azide inhibiting energy formation reactions. J Biochem 76: 667–669. PMID: 4279912

34. Moody AJ, Mitchell R, Jeal AE, Rich PR (1997) Comparison of the ligand-binding properties of native and copper-less cytochromes b from Escherichia coli. Biochem J 324 (Pt 3): 745–752. PMID: 9210397

35. Price CE, Driessen AJ (2010) Biogenesis of membrane bound respiratory complexes in Escherichia coli. Biochim Biophys Acta 1803: 748–766. doi: 10.1016/j.bbamcr.2010.01.019 PMID: 20138092
36. Zhang JH, Chung TD, Oldenburg KR (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67–73. PMID: 10838414
37. Yoshida M, Muneyuki E, Hisabori T (2001) ATP synthase—a marvellous rotary engine of the cell. Nat Rev Mol Cell Biol 2: 669–677. PMID: 11533724
38. Brandt U (2006) Energy converting NADH:quinone oxidoreductase (complex I). Annu Rev Biochem 75: 69–92. PMID: 1765485
39. Efremov RG, Sazanov LA (2011) Structure of the membrane domain of respiratory complex I. Nature 476: 414–420. doi:10.1038/nature10330 PMID: 21822288
40. Juliana C, Fernandes-Alnemri T, Wu J, Datta P, Solorzano L, Yu JW, et al. (2010) Anti-inflammatory compounds parthenolide and Bay 11–7082 are direct inhibitors of the inflammasome. J Biol Chem 285: 9792–9802. doi: 10.1074/jbc.M109.082305 PMID: 20993358
41. Whitaker N, Bageshwar UK, Musser SM (2012) Kinetics of precursor interactions with the bacterial Tat translocase detected by real-time FRET. J Biol Chem 287: 9802–9813. doi:10.1074/jbc.M112.324525 PMID: 22315217
42. Dhillon GS, Kaur S, Pulicharla R, Brar SK, Cledon M, Verma M, et al. (2015) Triclosan: current status, occurrence, environmental risks and bioaccumulation potential. Int J Environ Res Public Health 12: 8570–8593. PMID: 26016133
43. Yazdankhah SP, Scheie AA, Hoiby EA, Lunestad BT, Heir E, Fotland TO, et al. (2006) Triclosan and antimicrobial resistance in bacteria: an overview. Microb Drug Resist 12: 83–90. PMID: 16922622
44. Russell AD (2004) Whither triclosan? J Antimicrob Chemother 53: 693–695. PMID: 15073159
45. Yueh MF, Taniguchi K, Chen S, Evans RM, Hammock BD, Karin M, et al. (2014) The commonly used antimicrobial additive triclosan is a liver tumor promoter. Proc Natl Acad Sci U S A 111: 17200–17205. doi: 10.1073/pnas.1419119111 PMID: 25404284
46. Pereira DA, Williams JA (2007) Origin and evolution of high throughput screening. Br J Pharmacol 152: 53–61. PMID: 17603542
47. Forman SA, Chiara DC, Miller KW (2015) Anesthetics target interfacial transmembrane sites in nicotinic acetylcholine receptors. Neuropharmacology 96: 169–177. doi: 10.1016/j.neuropharm.2014.10.002 PMID: 25316107
48. Proudfoot AE, Bonvin P, Power CA (2015) Targeting chemokines: Pathogens can, why can't we? Cyto-kine 74: 259–267. doi: 10.1016/j.cyto.2015.02.011 PMID: 25753743
49. Wang X, Smith C, Yin H (2013) Targeting Toll-like receptors with small molecule agents. Chem Soc Rev 42: 4859–4866. doi: 10.1039/c3cs60039d PMID: 23503527
50. Koch S, Fritsch MJ, Buchanan G, Palmer T (2012) Escherichia coli TatA and TatB proteins have N-out, C-in topology in intact cells. J Biol Chem 287: 14420–14431. doi: 10.1074/jbc.M112.354555 PMID: 22399293
51. Aldridge C, Ma X, Gerard F, Cline K (2014) Substrate-gated docking of pore subunit Tha4 in the TatC cavity initiates Tat translocase assembly. J Cell Biol 205: 51–65. doi: 10.1083/jcb.201311057 PMID: 24711501
52. Ma X, Cline K (2013) Mapping the signal peptide binding and oligomer contact sites of the core subunit of the pea twin arginine protein translocase. Plant Cell 25: 999–1015. doi: 10.1105/tpc.112.107409 PMID: 23512851
53. Bageshwar UK, Whitaker N, Liang FC, Musser SM (2009) Interconvertibility of lipid- and translocon-bound forms of the bacterial Tat precursor pre-SufI. Mol Microbiol. 2009/09/08 ed. pp. 209–226. doi: 10.1111/j.1365-2958.2009.06862.x PMID: 19732346
54. Wexler M, Sargent F, Jack RL, Stanley NR, Bogsch EG, Robinson C, et al. (2000) TatD is a cytoplasmic protein with DNase activity. No requirement for TatD family proteins in sec-independent protein export. J Biol Chem 275: 16717–16722. PMID: 10747959
55. Casadaban MJ, Cohen SN (1979) Lactose genes fused to exogenous promoters in one step using a Mu-lac bacteriophage: in vivo probe for transcriptional control sequences. Proc Natl Acad Sci U S A 76: 4530–4533. PMID: 159458
59. Lindenstrauss U, Matos CF, Graubner W, Robinson C, Bruser T (2010) Malfolded recombinant Tat substrates are Tat-independently degraded in *Escherichia coli*. FEBS Lett 584: 3644–3648. doi: 10.1016/j.febslet.2010.07.039 PMID: 20659466

60. Thomas JD, Daniel RA, Errington J, Robinson C (2001) Export of active green fluorescent protein to the periplasm by the twin-arginine translocase (Tat) pathway in *Escherichia coli*. Mol Microbiol 39: 47–53. PMID: 11123687

61. Tu LC, Fu G, Zilman A, Musser SM (2013) Large cargo transport by nuclear pores: implications for the spatial organization of FG-nucleoporins. EMBO J 32: 3220–3230. doi: 10.1038/emboj.2013.239 PMID: 24213245

62. Liang FC, Bageshwar UK, Musser SM (2009) Bacterial Sec protein transport is rate-limited by precursor length: a single turnover study. Mol Biol Cell 20: 4256–4266. doi: 10.1091/mbc.E09-01-0075 PMID: 19656854

63. Durant JL, Leland BA, Henry DR, Nourse JG (2002) Reoptimization of MDL keys for use in drug discovery. J Chem Inf Comput Sci 42: 1273–1280. PMID: 12444722

64. Sebaugh JL (2011) Guidelines for accurate EC50/IC50 estimation. Pharm Stat 10: 128–134. doi: 10.1002/pst.426 PMID: 22328315